NSABP Members' Area
  Password Protected - Access
  Limited to NSABP Participating
  Institutions Only


NSABP Foundation, Inc.



General NSABP Information
  Financial Conflicts of
     Interest Policy
  Coalition Comment:
     Reconfiguration
  IOM Report Group Comment
  Contact the NSABP
  Pathology Section
  Future Meetings
  NSABP Newsletters
  Media Info on STAR
  Employment

Clinical Trials Information
  Clinical Trials Overview
  Protocol Chart
  Never Say Lost

Treatment Trials Information
  Protocol B-43
  Protocol B-47
  Protocol B-51

Prevention Trials Information
  Protocol P-1 - BCPT
  Protocol P-2 - STAR
  Protocol P-5
  BreastCancerPrevention.com

Scientific Publications

Related Web Sites



Medical Search Engines



To report problems, ask
questions or make comments,
please send e-mail to:
Webmaster@nsabp.pitt.edu

NSABP Clinical Trials Overview


Protocol B-20
A Clinical Trial to Determine the Worth of Chemotherapy and Tamoxifen over Tamoxifen Alone in the Management of Patients with Primary Invasive Breast Cancer, Negative Axillary Nodes and Estrogen-Receptor-Positive Tumors

Specific Aims
The aims of this study are twofold: to determine whether the addition of combination chemotherapy will improve the benefit of tamoxifen in this group of patients, and, if so, to determine whether an alkylating agent is required when the chemotherapy is given with tamoxifen.

Specifically, the study goals are:
  1. to determine whether six cycles of sequential methotrexate and 5-fluorouracil (M→F) followed by leucovorin, when added to tamoxifen (M→F+T), are more effective than tamoxifen alone;
  2. to determine whether six cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF), when added to tamoxifen (CMF+T), are more effective than tamoxifen;
  3. to determine whether CMF+T is more effective than M→F+T. End points for evaluation of treatment effectiveness include survival and disease-free survival.
A secondary objective is to relate tumor cell ploidy, kinetics, and nuclear grade to patient outcome.